左旋门冬酰胺酶治疗急性淋巴性白血病时凝血功能的观察
|
摘要
目的观察左旋门冬酰胺酶(L-ASP)治疗急性淋巴性白血病(ALL)时对患者凝血功能的影响。方法2012年6月到2015年5月共收集64例ALL患者作为研究对象,随机分为对照组、观察组各32例,两组均给予常规化疗,观察组加用,监测治疗前、后患者凝血酶原时间(PT)、部分凝血活酶时间(a PTT)、凝血酶时间(TT)、纤维蛋白酶(Fbg)、D二聚体(D-D)、外周血小板计数(PLT)等指标的变化,统计两组治疗不良反应发生率。结果治疗前,两组PT、a PTT、TT对比差异无统计学意义(P>0.05);L-ASP治疗4 d,观察组PT、a PTT、TT均延长,而对照组无明显变化(P<0.05),治疗结束3 d,观察组PT、a PTT、TT均缩短,与对照组相比差异无统计学意义(P>0.05);治疗前,两组Fbg、DD、PLT对比时下差异无统计学意义(P>0.05);左旋门冬酰胺酶治疗4 d,观察组Fbg降低,D-D、PLT上升,与对照组相比差异有统计学意义(P<0.05),治疗结束3 d,观察组Fbg上升,D-D、PLT有所降低,其Fbg、D-D与对照组相比差异仍有统计学意义(P<0.05);结论采用L-ASP治疗ALL可导致患者凝血机制异常,但停药后可恢复。
Objective To analyze effects of L-asparaginase( L-ASP) on coagulation indexes of patients with acute lymphoid leukemia( ALL). Methods 64 patients with ALL from June 2012 to May 2015 were enrolled in the study,they were divided by random number table into the control group and the observation group( each 32 cases),the two groups were given conventional chemotherapy,the observation group added lasparaginase intervention,before the treatment,after the treatment,patients' prothrombin time( PT),activated partial thromboplastin time( a PTT),thrombin time( TT),fibrin ferment( Fbg),D-dimer( D-D),peripheral blood platelet count( PLT) and other indexes were monitored,incidence of adverse drug reactions in the two groups were recorded. Results Before the treatment,there was no significant difference in PT,a PTT and TT in the two groups( P > 0. 05); 4 d of lasparaginase treatment,PT,a PTT and TT in the observation group were significantly prolonged( P < 0. 05),3 d after the treatment,PT,a PTT and TT of the observation group were slightly shortened compared with the control group( P > 0. 05); before the treatment,there was no significant difference in Fbg,D-D and PLT in the two groups( P > 0. 05); 4 d of lasparaginase treatment,Fbg of the observation group was significantly reduced,D-D and PLT were significantly increased compared with the control group( P < 0. 05),3 d after the treatment,Fbg of the observation group was increased,D-D and PLT were decreased,there was a significant difference in Fbg and D-D compared with the control group( P <0. 05). Conclusion Application of L-ASP in treating ALL can lead to coagulation function anomaly,but it can return normal after withdrawal the medications,has its reversibility.
Objective To analyze effects of L-asparaginase( L-ASP) on coagulation indexes of patients with acute lymphoid leukemia( ALL). Methods 64 patients with ALL from June 2012 to May 2015 were enrolled in the study,they were divided by random number table into the control group and the observation group( each 32 cases),the two groups were given conventional chemotherapy,the observation group added lasparaginase intervention,before the treatment,after the treatment,patients' prothrombin time( PT),activated partial thromboplastin time( a PTT),thrombin time( TT),fibrin ferment( Fbg),D-dimer( D-D),peripheral blood platelet count( PLT) and other indexes were monitored,incidence of adverse drug reactions in the two groups were recorded. Results Before the treatment,there was no significant difference in PT,a PTT and TT in the two groups( P > 0. 05); 4 d of lasparaginase treatment,PT,a PTT and TT in the observation group were significantly prolonged( P < 0. 05),3 d after the treatment,PT,a PTT and TT of the observation group were slightly shortened compared with the control group( P > 0. 05); before the treatment,there was no significant difference in Fbg,D-D and PLT in the two groups( P > 0. 05); 4 d of lasparaginase treatment,Fbg of the observation group was significantly reduced,D-D and PLT were significantly increased compared with the control group( P < 0. 05),3 d after the treatment,Fbg of the observation group was increased,D-D and PLT were decreased,there was a significant difference in Fbg and D-D compared with the control group( P <0. 05). Conclusion Application of L-ASP in treating ALL can lead to coagulation function anomaly,but it can return normal after withdrawal the medications,has its reversibility.
引文
[1]宋森花,王军,徐彪,等.左旋门冬酰胺酶治疗急性淋巴细胞白血病期间凝血功能异常处理的意义[J].临床军医杂志,2011,39(5):887-888.
[2]史红鱼,郝国平,常虹,等.左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的不良反应及防治[J].白血病·淋巴瘤,2011,20(1):52-54.
[3]张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2007:131-134.
[4]叶丽,虞国慧,潘明,等.左旋门冬酰胺酶治疗急性淋巴细胞白血病不良反应[J].安徽医药,2011,15(3):365-366.
[5]王岳,李学荣,仲任,等.培门冬酶和左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效和安全性[J].药物不良反应杂志,2011,13(5):278-282.
[6]吕琳琳.急性早幼粒细胞白血病出血与血栓形成机制[J].血栓与止血学,2013,19(1):41-43.
[7]陈岩岩,黄科,郭海霞,等.门冬酰胺酶致儿童急性淋巴细胞白血病脑血栓形成2例[J].中国小儿血液与肿瘤杂志,2012,17(3):136-137.
[2]史红鱼,郝国平,常虹,等.左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的不良反应及防治[J].白血病·淋巴瘤,2011,20(1):52-54.
[3]张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2007:131-134.
[4]叶丽,虞国慧,潘明,等.左旋门冬酰胺酶治疗急性淋巴细胞白血病不良反应[J].安徽医药,2011,15(3):365-366.
[5]王岳,李学荣,仲任,等.培门冬酶和左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效和安全性[J].药物不良反应杂志,2011,13(5):278-282.
[6]吕琳琳.急性早幼粒细胞白血病出血与血栓形成机制[J].血栓与止血学,2013,19(1):41-43.
[7]陈岩岩,黄科,郭海霞,等.门冬酰胺酶致儿童急性淋巴细胞白血病脑血栓形成2例[J].中国小儿血液与肿瘤杂志,2012,17(3):136-137.